
Global R&D Pipeline
My Favorite
Hot Targets:
4-1BB
Back
Total number of drugs
221
Phase II and later clinical stages
7.2%
Involving companies
194
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD-1 dependent 4-1BB agonist(Auburn University) | PD-1 dependent 4-1BB agonist(Auburn University) | Nanobody Bispecific antibody | Neoplasms | 4-1BB agonists PD-1 inhibitors | Auburn University College of Veterinary Medicine | Auburn University College of Veterinary Medicine | Preclinical | - | - | - | - | - | - | - | - | PD-1 dependent 4-1BB agonist(Auburn University) | - | - | detail > | ||
| Pro-Urelumab | Pro-Urelumab | Monoclonal antibody | Neoplasms | 4-1BB agonists | Kaohsiung Medical University | Kaohsiung Medical University | Preclinical | - | - | - | - | - | - | - | - | Pro-Urelumab | - | - | detail > | ||
| 7A5 (Eli Lilly & Co.) | 7A5 (Eli Lilly & Co.) | Monoclonal antibody | Neoplasms | 4-1BB agonists | Eli Lilly & Co. | Eli Lilly & Co. | Preclinical | - | - | - | - | - | - | - | - | 7A5 (Eli Lilly & Co.) | - | - | detail > | ||
| Anti-4-1bb/PD-1/VISTA mAbs (The University of Queensland) | Anti-4-1bb/PD-1/VISTA mAbs (The University of Queensland) | Trispecific antibody | Neoplasms | 4-1BB agonists PD-1 inhibitors VISTA inhibitors | The University of Queensland | The University of Queensland | Preclinical | - | - | - | - | - | - | - | - | Anti-4-1bb/PD-1/VISTA mAbs (The University of Queensland) | - | - | detail > | ||
| TJ-MU4B | TJ-MU4B | Bispecific antibody | Neoplasms | 4-1BB agonists | I-MAB Biopharma Co., Ltd. | I-MAB Biopharma Co., Ltd. | Preclinical | - | - | - | - | - | - | - | - | TJ-MU4B | - | - | detail > | ||
| NBL-016 | NBL-016 | Bispecific antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | 4-1BB agonists CLDN18.2 modulators | Novarock Biotherapeutics Ltd. | Novarock Biotherapeutics Ltd. | Preclinical | - | - | - | - | - | - | - | - | NBL-016 | - | - | detail > | ||
| M9657 | M9657 | Bispecific antibody | Neoplasms | 4-1BB agonists MSLN inhibitors PD-1 inhibitors | EMD Serono Research & Development Institute, Inc. | EMD Serono Research & Development Institute, Inc. | Preclinical | - | - | - | - | - | - | - | - | M9657 | - | - | detail > | ||
| APVO-603 | APVO-603 | Bispecific antibody | Neoplasms | 4-1BB agonists OX40 agonists ADCC | Aptevo Therapeutics, Inc. | Aptevo Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | APVO-603 | - | - | detail > | ||
| 4-1BB/Nectin-4 bispecific antibody (Twist Bioscience) | 4-1BB/Nectin-4 bispecific antibody (Twist Bioscience) | Bispecific antibody | Neoplasms | 4-1BB agonists nectin-4 inhibitors | Twist Bioscience Corp. | Twist Bioscience Corp. | Preclinical | - | - | - | - | - | - | - | - | 4-1BB/Nectin-4 bispecific antibody (Twist Bioscience) | - | - | detail > | ||
| ABL112 | ABL112 | Bispecific antibody | Neoplasms | 4-1BB agonists TIGIT inhibitors | ABL Bio, Inc. | ABL Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | ABL112 | - | - | detail > |
Total 221 data
1
2
3
4
5
6
...
22
23


